Envoy Medical Inc. held its 2025 Annual Meeting of Stockholders on May 28, 2025. During the meeting, stockholders elected two Class II director nominees to the Board of Directors. The appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. An amendment to the Envoy Medical, Inc. 2023 Equity Incentive Plan was approved, removing the restriction on 1,500,000 shares of common stock previously unavailable for issuance until a regulatory milestone was achieved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.